



Date: July 24, 2025

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex Bandra (East) <u>Mumbai – 400 051</u> Stock Code : INDOCO	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, <u>Mumbai – 400 001</u> Stock Code : 532612
--	---

Dear Sir/Madam,

Sub: Indoco Remedies Limited receives Certificate of EU GMP Compliance from the European Health Authorities for the sterile drug product manufacturing facility, Goa Plant II

Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received Certificate for EU Good Manufacturing Practices (GMP) Compliance from the European Health Authorities for its sterile drug product manufacturing facility, Goa Plant II located at L32, 33 and 34, Verna Industrial Estate, South Goa-403722.

Please find enclosed herewith press release in this regard.

This is for your information and records.

Thanking you,
Yours faithfully,
For Indoco Remedies Limited

Ramanathan Hariharan
Company Secretary & Head- Legal





PRESS RELEASE

Indoco receives Certificate of EU GMP Compliance from the European Health Authorities for its sterile drug product manufacturing facility, Goa Plant II

Mumbai, July 24, 2025: Indoco Remedies Limited announced that the Company has received Certificate for EU Good Manufacturing Practices (GMP) Compliance from the European Health Authorities for its sterile drug product manufacturing facility, Goa Plant II located at L32, 33 and 34, Verna Industrial Estate, South Goa-403722.

The EU GMP certification issued by the European Health Authorities confirms that the site complies with the Good Manufacturing Practice requirements.

Commenting on the development, **Ms. Aditi Panandikar, Managing Director, Indoco Remedies Ltd.** said, "This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies. We remain fully committed to adhering to cGMP standards and consistently delivering quality products to customers and patients worldwide."

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 180 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization.

The Company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,40,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subital, Rexidin, MCBM 69, Methycal, Dropizin, Noxa, Homide, Cal-Aid, Ninaf, Cital-Ui, Otorex, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media enquiries please contact:

Corporate Communications | +91 22 62871000

E-mail: corpcom@indoco.com